Paradigm Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Paradigm Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,600	Closed	-$465K	–	525
2017 Q2	$465K	Sell	17,600 -18,100	-51%	-$404K	0.09%	238
2017 Q1	$743K	Buy	+35,700	New	+$733K	0.14%	168
2016 Q2	–	Sell	-3,000	Closed	-$52.4K	–	835
2016 Q1	$52.4K	Hold	3,000	–	–	0.01%	576
2015 Q4	$102K	Buy	+3,000	New	+$104K	0.02%	493
2014 Q3	–	Sell	-1,900	Closed	-$64.6K	–	876
2014 Q2	$64.6K	Buy	+1,900	New	+$59.5K	0.01%	690

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Paradigm Asset Management's RVNC Position: Q3 2017 in Review

Paradigm Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2017, closing a stake of 17,600 shares — an estimated $465K sold.

Paradigm Asset Management first reported a position in RVNC in Q2 2014 and held it in 5 quarters. The position peaked at $743K in Q1 2017. 85 funds tracked by Wall St. Rank hold RVNC as of Q3 2017.

Paradigm Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 17,600 Revance Therapeutics, Inc. shares in Q3 2017, an estimated $465K.
Paradigm Asset Management first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
Paradigm Asset Management's Revance Therapeutics, Inc. position peaked at $743K in Q1 2017.
85 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.